Answers are grounded in this paper and cite their sources.
On January 1, 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1s indicated for weight management. In 2025 Q4 these four states accounted for 60.5% of Medicaid weight-management GLP-1 prescriptions nationally (661,478 of 1,094,191). We used State Drug Utilization Data from 2024 Q1 through 2026 Q1 to describe dispensing in the first quarter after withdrawal, classifying products by FDA-approved indication. In the withdrawing states, weight-management GLP-1 prescriptions were 1.06 per 100 enrollee-months in 2025 Q3, 1.08 in 2025 Q4, and 0.16 in 2026 Q1, a decline of 85%, while in six states that kept coverage the same figures were 0.90, 0.97, and 0.82. The difference-in-differences estimate was -0.67 (95% CI, -1.21 to -0.18). Gross reimbursement in the withdrawing states fell by $1,079 per 100 enrollee-months from 2025 Q3 to 2026 Q1. Dispensing of GLP-1s labeled for other indications did not rise: the estimate against 33 never-covering states was -0.03 (95% CI, -0.29 to 0.23), so increases larger than 0.23 per 100 enrollee-months, about one quarter of the weight-management decline, can be ruled out. Substitution toward diabetes-labeled products was at most limited in the first quarter after coverage ended.
No takes yet. Share an insight, caveat, or question.
Lo et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: